2783

Oligonucleotide based therapy (by modulation of MKNK2 alternative splicing) as novel cancer therapy

Karni Rotem, HUJI, School of Medicine - IMRIC, Biochemistry and Molecular Biology
Additional material on the technology can be supplied upon request

Patent Status

Granted US 9,745,581

Contact for more information:

Shoshana Keynan
VP, Head of Business Development, Healthcare
+972-2-6586683
Contact ME:
Image CAPTCHA